文献速递肿瘤 PET/CT放射性药物与辐射防护

连续多示踪剂PET/CT表征肝损伤炎症-纤维化轴

Serial Multitracer PET/CT for Characterization of the Inflammation-Fibrosis Axis in Liver Injury.
PubMed 文献 · J Nucl Med · 2026-09-24

研究在CCl4诱导的小鼠肝纤维化损伤模型中,于基线、纤维化前炎症期、纤维化期和消退期进行系列多示踪剂PET/CT,评估其表征疾病进展与消退的可行性。结果显示[18F]FDG在纤维化前和纤维化期摄取增高,[68Ga]Ga-pentixafor在纤维化前炎症期达峰,αvβ6整合素在纤维化期升高,而两种FAP示踪剂摄取意外降低。靶向分子成像可表征肝损伤反应,但FAP配体价值有限。

要点

  • [18F]FDG在纤维化前和纤维化期肝摄取增高,提示葡萄糖利用增加。
  • [68Ga]Ga-pentixafor在纤维化前炎症期达峰,与CD68阳性细胞丰富一致。
  • αvβ6整合素在纤维化期升高,而两种FAP示踪剂摄取在纤维化前和纤维化期均降低。

核心结论

  • 肝损伤激活炎症-纤维化轴与肝葡萄糖利用增加相关。
  • 趋化因子受体4靶向可特异性识别肝组织炎症,αvβ6整合素可识别纤维化活性。
  • 靶向分子成像表征肝损伤反应可行,为抗纤维化治疗影像引导提供基础,但FAP配体在本模型价值有限。

研究设计与样本

  • C57BL/6N小鼠(n=31)腹腔注射四氯化碳(CCl4),在基线、CCl4 3周(纤维化前炎症期)、CCl4 6周(纤维化期)和停止CCl4后3周(消退期)进行系列PET/CT。
  • PET/CT示踪剂包括代谢标志物[18F]FDG、白细胞标志物[68Ga]Ga-pentixafor(趋化因子[C-X-C基序]受体4配体)、2种成纤维细胞活化蛋白(FAP)标志物[68Ga]Ga-MHLL2和[68Ga]Ga-FAP抑制剂(FAPI)-46、αvβ6整合素配体[68Ga]Ga-trivehexin。
  • 相关测量包括血清生物标志物、体外细胞实验和组织分析。

主要发现

  • CCl4给药导致肝转氨酶升高,消退期可逆,伴大体形态改变、组织学巨噬细胞-单核细胞浸润和胶原沉积增加。
  • 肝[18F]FDG摄取在纤维化前期(P=0.005)和纤维化期(P=0.049)较基线增高。
  • [68Ga]Ga-pentixafor在纤维化前期达峰(P=0.003),与组织学观察到的CD68阳性细胞丰富一致。
  • αvβ6整合素在纤维化期升高(P=0.038);两种FAP示踪剂摄取在纤维化前期([68Ga]Ga-MHLL2,P=0.001;[68Ga]Ga-FAPI-46,P=0.001)和纤维化期([68Ga]Ga-MHLL2,P<0.001;[68Ga]Ga-FAPI-46,P=0.001)降低,尽管组织学证实FAP阳性星状细胞。
  • 体外细胞实验显示FAP示踪剂快速细胞外排,可能限制其在FAP表达损伤组织中的特异性积聚。

临床怎么用

  • 靶向分子成像可用于表征肝损伤后的炎症与纤维化活动,为抗纤维化治疗提供影像引导基础。
  • 趋化因子受体4靶向显像可识别肝组织炎症,αvβ6整合素显像可识别纤维化活性。
  • FAP配体在本模型中价值有限,需进一步研究。

局限性

  • 研究为小鼠模型,结果外推至临床需谨慎。
  • FAP示踪剂因快速细胞外排可能限制特异性积聚,其价值需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As the global burden of liver disease is increasing, the interplay between inflammation and fibrosis is emerging as a promising target for antifibrotic hepatic therapies. Such advanced interventions will require biomarker guidance, which is an opportunity for molecular imaging. We tested the feasibility of multiple radiopharmaceuticals to characterize disease progression and regression in a mouse model of fibrotic liver injury. Methods: C57BL/6N mice (n = 31) received intraperitoneally injected carbon tetrachloride (CCl4) along with serial PET/CT at baseline, in the prefibrotic inflammatory phase (3 wk of CCl4), in the fibrosis phase (6 wk of CCl4), and in the regression phase (3 wk after termination of CCl4). PET/CT included the metabolic marker [18F]FDG; the leukocyte marker [68Ga]Ga-pentixafor (chemokine [C-X-C motif] receptor 4 ligand); 2 fibroblast activation protein (FAP) markers, [68Ga]Ga-MHLL2 and [68Ga]Ga-FAP inhibitor (FAPI)-46; and the αvβ6-integrin ligand [68Ga]Ga-trivehexin. Correlative measurements included serum biomarkers, in vitro cell assays, and tissue analyses. Results: CCl4 administration led to elevation of liver transaminases, which was reversible in the regression phase. This was associated with gross morphologic changes, histologic macrophage-monocyte infiltration, and increased collagen deposition. Hepatic [18F]FDG uptake increased in the prefibrosis phase (P = 0.005) and the fibrosis phase (P = 0.049) compared with baseline. [68Ga]Ga-pentixafor reached its peak in the prefibrosis phase (P = 0.003), consistent with the abundance of CD68-positive cells observed upon histology. Although αvβ6-integrin, as a marker of profibrotic activity, was elevated as expected in the fibrosis phase (P = 0.038), we found a surprising reduction of uptake of both FAP tracers in the prefibrosis phase ([68Ga]Ga-MHLL2, P = 0.001; [68Ga]Ga-FAPI-46, P = 0.001) and the fibrosis phase ([68Ga]Ga-MHLL2, P < 0.001; [68Ga]Ga-FAPI-46, P = 0.001), despite histologic proof of FAP-positive stellate cells. In vitro cell assays showed a fast cellular efflux of FAP tracers, potentially limiting specific accumulation in FAP-expressing injured tissue. Conclusion: Activation of the inflammation-fibrosis axis by liver injury is associated with stimulated hepatic glucose utilization. Chemokine receptor 4 targeting specifically identifies hepatic tissue inflammation, whereas αvβ6-integrin identifies fibrotic activity. This supports the feasibility of targeted molecular imaging to characterize hepatic response to injury and provides a foundation for image guidance of antifibrotic therapies. The value of FAP ligands was limited in our model and requires further investigation.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Teuter M, Balakrishnan A, Hu Y, et al. Serial Multitracer PET/CT for Characterization of the Inflammation-Fibrosis Axis in Liver Injury. J Nucl Med. 2026. PMID: 42785952. doi:10.2967/jnumed.126.273298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。